Shots:
- Dyadic to receive $10M up front in cash & stock and ~$4M in reimbursements for pre/ clinical development costs for DYAI-100 vaccine & ~ $33M in milestone along with royalties following commercialization
- Sorrento acquire exclusive rights to use Dyadic’s C1 technology to develop and commercialize vaccines, Abs, protein therapeutics, and diagnostics for COVID-19, including DYAI-100 in the EU, America, Asian countries including Greater China and Japan. Additionally, Sorrento will be responsible for all future development cost related to the license agreement
- Dyadic’s DYAI-100 will utilize SARS-CoV-2 spike protein RBD & is produced using patented C1-cell protein production platform
Click here to read full press release/ article | Ref: Sorrento | Image: Analyze Markets
The post Sorrento to License Dyadic’s DYAI-100 and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics first appeared on PharmaShots.
